Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

The present invention relates to a complex comprising a transition metal cation (i); a ligand (ii) comprising at least one chelating group, preferably from 1 to 4 chelating groups, more preferred 2 or 3 chelating groups, wherein the chelating group(s) is/are selected from hydroxamate group —N(O″)—C(═O)—R, catechol ate group, carboxyl ate group, partly or totally protonated forms of these chelating groups and mixtures of these chelating groups and/or their partly or totally protonated forms, wherein R is hydrogen or a C1 to C5 alkyl group; and a magnetic bead (iii); wherein the magnetic bead (iii) and the ligand (ii) are covalently bonded. The invention also relates to the use of the complex for reduction of the content of at least one phosphor-oxy-substance, which preferably comprises a structural element —O—P(O″)(═O)—O— within its structure, in a fluid sample, as well as to a method for decreasing the content of at least one phosphor-oxy-substance, preferably a phospholipid, in a fluid sample, comprising a step of adding the complex. The invention further relates to a supernatant obtained or obtainable from this method and to the use of a supernatant obtained or obtainable from the method for qualitative and/or quantitative determination of at least one analyte in said supernatant. Furthermore, the invention relates to a method for qualitative and/or quantitative determination of at least one analyte in a fluid sample and to a method for determining the kind and/or amount of at least one phosphor-oxy-substance in a fluid sample.

Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

The invention relates to methods for encapsulating a material comprising the steps of: (a) providing an aqueous solution or suspension of the material that is to be encapsulated, (b) warming the aqueous solution or suspension to a temperature that is sufficient to enable dissolution of a first biocompatible polymer in the aqueous solution or suspension without adversely affecting the properties of the material to be encapsulated, (c) dissolving the first biocompatible polymer in the aqueous solution or suspension, (d) de-aerating the solution or suspension obtained in step (c), (e) emulsifying the solution or suspension obtained in (d) in a biocompatible oil comprising a surfactant to create microdroplets, and (f) hardening the microdroplets by dropwise addition of an aqueous solution comprising Zn.sup.2+ ions and a second biocompatible polymer to form microcapsules; the invention further relates to microcapsules obtained by methods of the invention and their uses.